Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Exclusion Criteria

• •Subjects with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before the administration of investigational drug
• •Subjects who have a history 2 times or more of varicella vaccine injections
• •Subjects who had an acute febrile (at least 38.0 ℃) episode at some time during the 72 hours before the administration of investigational product
• •Subjects who had any suspected allergy symptoms including systemic rash during the 72 hours before the administration of investigational product
• •Subjects with a history of Guillain-Barre syndrome.
• •Subjects with a severe chronic disease and considered ineligible for the study at Investigator's discretion
• •Subjects with a history of hypersensitivity to any ingredient such as gelatin, antibiotics (Neomycin, Kanamycin, Erythromycin)
• •Active tuberculosis patient
• •Subjects who had received other vaccinations within 4 weeks before the administration of investigational product
• •Subjects with immunodeficiency history
• •Subjects who had received salicylates (aspirin, bismuth, subsalicylates) within 4 weeks before the administration of investigational drug
• •Subjects who administered immune globulin, gamma globulin, or blood products such as whole blood within 44 weeks before the administration of investigational drug
• •Subjects who had received immunosuppressant or immune modifying drug within 12 weeks before the administration of investigational drug
• •A. Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, etc.
• •B. Subjects who administered high dose of corticosteroids (greater than 2 mg/kg/day in case of under 10kg subjects or ≥20mg/day in case of above 10kg subject of prednisone for 14 days) (However, inhaled, intranasal, topical corticosteroids administration in allowed)
• •Subjects who administered anti-viral drug within 4 weeks before the administration of investigational drug
• •Subjects who have participated in any other clinical trials within 24 weeks of the administration of the investigational product
• •Subjects with other clinically significant medical or psychological condition who are considered by the Investigator to be ineligible for the study